Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
Hiromichi Ebi1, Anthony C Faber, Jeffrey A Engelman
1Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan.
Abstract:
Mutations in Kirsten rat-sarcoma (KRAS) are well appreciated to be major drivers of human cancers through dysregulation of multiple growth and survival pathways. Similar to many other non-kinase oncogenes and tumor suppressors, efforts to directly target KRAS pharmaceutically have not yet materialized. As a result, there is broad interest in an alternative approach to develop therapies that induce synthetic lethality in cancers with mutant KRAS, therefore exposing the particular vulnerabilities of these cancers. Fueling these efforts is our increased understanding into the biology driving KRAS mutant cancers, in particular the important pathways that mutant KRAS governs to promote survival. In this mini-review, we summarize the latest approaches to treat KRAS mutant cancers and the rationale behind them.
Insights
Targeting Kirsten rat-sarcoma (KRAS) mutations in cancer is challenging. This review explores novel synthetic lethality strategies to exploit KRAS-mutant cancer vulnerabilities.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Mutations in Kirsten rat-sarcoma (KRAS) are key drivers in numerous human cancers.
- Directly targeting KRAS oncogenes with drugs has proven difficult.
- Understanding KRAS-driven pathways is crucial for developing new cancer therapies.
Purpose of the Study:
- To review current therapeutic strategies for KRAS-mutant cancers.
- To highlight the rationale behind targeting KRAS vulnerabilities.
- To summarize recent advancements in treating KRAS-driven malignancies.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of molecular pathways regulated by mutant KRAS.
- Synthesis of information on synthetic lethality approaches.
Main Results:
- KRAS mutations dysregulate critical growth and survival pathways.
- Synthetic lethality offers a promising alternative to direct KRAS inhibition.
- Emerging therapies exploit specific vulnerabilities in KRAS-mutant cancer cells.
Conclusions:
- Targeting KRAS-mutant cancers requires innovative therapeutic approaches.
- Synthetic lethality strategies show significant potential for clinical application.
- Continued research into KRAS biology will drive future treatment developments.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38The Ras Gene
Ras is a...
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...